Improvements seen for corneal epithelial damage, dryness symptoms
By Lori Solomon HealthDay Reporter
MONDAY, April 10, 2023 (HealthDay News) — A water-free cyclosporine solution is effective for treating moderate-to-severe dry eye disease (DED), according to a study published online April 6 in JAMA Ophthalmology.
Esen K. Akpek, M.D., from Johns Hopkins University in Baltimore, and colleagues evaluated whether water-free cyclosporine eye drop, 0.1 percent, is effective in treating DED. The analysis included 834 study participants randomly assigned to twice-daily cyclosporine solution or vehicle for 29 days.
The researchers found that participants treated with cyclosporine solution had greater improvement in total corneal fluorescein staining (tCFS) than the vehicle group (−4.0 versus −3.6 grades) at day 29 (change [∆], −0.4; 95 percent confidence interval [CI], −0.8 to 0; P = 0.03). Treatment benefits in the dryness score from baseline were seen in both groups: −12.2 points for cyclosporine and −13.6 points for vehicle (∆ = 1.4; 95 percent CI, −1.8 to 4.6; P = 0.38). Clinically meaningful reductions of three grades or higher in tCFS were achieved by 71.6 percent in the cyclosporine group versus 59.7 percent in the vehicle group (∆ = 12.6 percent; 95 percent CI, 6.0 to 19.3 percent; P < 0.001). Compared with nonresponders, these responders showed greater improvement in symptoms at day 29, including dryness (∆ = −4.6; 95 percent CI, −8.0 to −1.2; P = 0.007) and blurred vision (Δ = −3.5; 95 percent CI, −6.6 to −4.0; P = 0.03).
“The rapid onset and magnitude of improvements on the corneal epithelial damage are potential differentiators to existing therapies,” the authors write.
Several authors disclosed ties to Novaliq, which funded the study.
Editorial (subscription or payment may be required)
Copyright © 2023 HealthDay. All rights reserved.
